BRAF or NRAS Mutant Metastatic Melanoma
1 clinical trials · Condition
◉ Watch BRAF or NRAS Mutant Metastatic Melanoma
| Record | Firm | Date |
|---|---|---|
| A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma (NCT01320085) | Pfizer | 2011-03-24 |
Track BRAF or NRAS Mutant Metastatic Melanoma automatically
Every clearance here is in the API, with alerts when new ones post.